Viewing data from:

NICOTINE POLACRILEX

ANDA

NICOTINE POLACRILEX | A209206 | P AND L DEVELOPMENT LLC

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 10 NDCs

Highest NADAC/Unit

$0.3477

per ea

Lowest NADAC/Unit

$0.3382

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00536133709NICOTINE 2 MG LOZENGE	$0.3477	EA	Generic	—	2026-06-17
00536133735NICOTINE 2 MG LOZENGE	$0.3477	EA	Generic	—	2026-06-17
70000056201NICOTINE 2 MG LOZENGE	$0.3477	EA	Generic	—	2026-06-17
46122073408GNP NICOTINE 2 MG LOZENGE	$0.3477	EA	Generic	—	2026-06-17
46122073462GNP NICOTINE 2 MG LOZENGE	$0.3477	EA	Generic	—	2026-06-17
00536133835NICOTINE 4 MG LOZENGE	$0.3382	EA	Generic	—	2026-06-17

Showing 6 of 10 NDCs.

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain10 active DMFs4 inactive

8 active API suppliers hold Drug Master Files for this ingredient.

NICOBRAND LTDNICOTINE POLACRILEX RESIN

DMF 107391994

CAMBREX CHARLES CITY INCNICOTINE POLACRILEX, 15%, USP

DMF 161662002

LABORATORIOS HAYMANN SANICOTINE POLACRILEX USP , 20%

DMF 169102003

FERTIN PHARMA ASNICOTINE POLACRILEX USP

DMF 201232007

SIEGFRIED LTDNICOTINE POLACRILEX 20%

DMF 221552008

BGP HEALTHCARE PRIVATE LTDNICOTINE POLACRILEX 20% USP

DMF 238382010

KENVUE BRANDS LLCNICOTINE POLACRILEX LOZENGE

DMF 322002018

FERTIN PHARMA ASNICOTINE POLACRILEX USP

DMF 356472021

NICOBRAND LTDNICOTINE POLACRILEX 20%

DMF 384412024

INDIA GLYCOLS LTDNICOTINE POLACRILEX USP

DMF 398692024

WYCKOFF CHEMICAL CO INCInactiveNICOTINE POLACRILEX

DMF 76541988

FINE CHEMICALS CORPInactiveNICOTINE POLACRILEX

DMF 105271993

SALSBURY CHEMICALS INCInactiveNICOTINE POLACRILEX RESIN

DMF 141931999

SMS PHARMACEUTICALS LTDInactiveNICOTINE POLACRILEX USP

DMF 219782008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jul 16, 2018	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — EQ 2MG BASE

0 patents0 exclusivities▴

TROCHE/LOZENGE;ORAL | Approved: Jun 26, 2018

No patent or exclusivity listings for this strength.

#002 — EQ 4MG BASE

0 patents0 exclusivities▾

TROCHE/LOZENGE;ORAL | Approved: Jun 26, 2018